A retrospective observational study of rapid titration of venetoclax (VEN) in patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). This is an ASCO Meeting Abstract from the ...
Two unique case reports highlight the diagnostic challenges and critical importance of comprehensive immunophenotyping in cases of T-cell acute lymphoblastic leukemia/lymphoma that present without ...
At the recent American Society of Hematology annual meeting, researchers presented preclinical data examining how transdifferentiation between hematopoietic lineages -- driven by LMO2 expression and ...
Acute lymphoblastic leukemia (ALL) may be confused with different types of hematological conditions. Confusion of ALL diagnosis with acute myeloid leukemia (AML), hairy cell leukemia and malignant ...
In the BRUIN Phase 1/2 trial, adult patients with CLL/SLL who have received at least two lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor, achieved an overall response rate of 72% ...
Pirtobrutinib had a nominally superior overall response rate compared to ibrutinib in certain patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The non-covalent ...
Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
Results from BRUIN CLL-321 show Lilly's pirtobrutinib reduced the risk of disease progression or death by 46% compared to idelalisib plus rituximab or bendamustine plus rituximab Pirtobrutinib ...
Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301) R1 compared induction ...
Pediatric non-Hodgkin’s lymphoma (NHL) is a type of cancer that may affect children. It occurs when cells in the immune system divide uncontrollably. Symptoms can depend on where the cancer develops.
With FDA approval to treat marginal zone lymphoma (MZL), Bristol Myers Squibb’s Breyanzi has become the first CAR-T therapy in the indication, as well as the first CAR-T to reach the market for five ...
Quality improvement research projects selected for funding to enhance care and improve outcomes in common blood cancers. PLYMOUTH MEETING, Pa., Dec. 4, 2024 /PRNewswire/ -- The National Comprehensive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback